

*Count*  
*BD*  
*Sub 61*  
*with*

wherein the rapidly precipitating drug is a fairly soluble or highly soluble salt form of a poorly soluble free base or free acid or anhydrous form of a poorly soluble free base or free acid, with the proviso that the rapidly precipitating drug is not delavirdine mesylate.

*13* 10. (Twice Amended) A non-sustained release, non-chewable pharmaceutical tablet composition according to Claim 9 where the microcrystalline cellulose is selected from the group consisting of

microcrystalline cellulose coarse powder

microcrystalline cellulose medium powder and

microcrystalline cellulose 200.

*13 4* 12. (Twice Amended) A non-sustained release, non-chewable pharmaceutical tablet composition according to Claim 9 where the microcrystalline cellulose is present in an amount of from about 10 to about 40%.

Pursuant to 37 CFR 1.121, a marked-up version of these amendments is enclosed herewith.

Please add new Claims 33 and 34 as follows:

*13 5* 33. (New) A tablet composition according to Claim 1, where the rapidly precipitating drug, binder and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding.

34. (New) A tablet composition according to Claim 1, wherein the binder is hydroxypropyl methylcellulose of from about 5% to about 20%.

#### REMARKS

Claims 1-24, 26, 30, 33 and 34 are pending in the application. Claims 33 and 34 were added with this amendment.